These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 19589292)

  • 41. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial.
    Krueger GG; Langley RG; Finlay AY; Griffiths CE; Woolley JM; Lalla D; Jahreis A
    Br J Dermatol; 2005 Dec; 153(6):1192-9. PubMed ID: 16307657
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial.
    Kalb RE; Blauvelt A; Sofen HL; Chevrier M; Amato D; Calabro S; Wang J; Schenkel B; Gottlieb AB
    J Drugs Dermatol; 2013 Aug; 12(8):874-80. PubMed ID: 23986160
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Economic evaluation of systemic therapies for moderate to severe psoriasis.
    Sizto S; Bansback N; Feldman SR; Willian MK; Anis AH
    Br J Dermatol; 2009 Jun; 160(6):1264-72. PubMed ID: 19120346
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Initial experience with routine administration of etanercept in psoriasis.
    de Groot M; Appelman M; Spuls PI; de Rie MA; Bos JD
    Br J Dermatol; 2006 Oct; 155(4):808-14. PubMed ID: 16965432
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Etanercept treatment for children and adolescents with plaque psoriasis.
    Paller AS; Siegfried EC; Langley RG; Gottlieb AB; Pariser D; Landells I; Hebert AA; Eichenfield LF; Patel V; Creamer K; Jahreis A;
    N Engl J Med; 2008 Jan; 358(3):241-51. PubMed ID: 18199863
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Switch to biological agent in psoriasis significantly improved clinical and patient-reported outcomes in real-world practice.
    Norlin JM; Steen Carlsson K; Persson U; Schmitt-Egenolf M
    Dermatology; 2012; 225(4):326-32. PubMed ID: 23328678
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy of etanercept in an integrated multistudy database of patients with psoriasis.
    Gordon K; Korman N; Frankel E; Wang H; Jahreis A; Zitnik R; Chang T
    J Am Acad Dermatol; 2006 Mar; 54(3 Suppl 2):S101-11. PubMed ID: 16488320
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction.
    Papp KA; Tyring S; Lahfa M; Prinz J; Griffiths CE; Nakanishi AM; Zitnik R; van de Kerkhof PC; Melvin L;
    Br J Dermatol; 2005 Jun; 152(6):1304-12. PubMed ID: 15948997
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Secukinumab in plaque psoriasis--results of two phase 3 trials.
    Langley RG; Elewski BE; Lebwohl M; Reich K; Griffiths CE; Papp K; Puig L; Nakagawa H; Spelman L; Sigurgeirsson B; Rivas E; Tsai TF; Wasel N; Tyring S; Salko T; Hampele I; Notter M; Karpov A; Helou S; Papavassilis C; ;
    N Engl J Med; 2014 Jul; 371(4):326-38. PubMed ID: 25007392
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Etanercept for the treatment of psoriasis: combination therapy with other modalities.
    Strober BE; Clarke S
    J Drugs Dermatol; 2004; 3(3):270-2. PubMed ID: 15176161
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Two years of experience with etanercept in recalcitrant psoriasis.
    Ahmad K; Rogers S
    Br J Dermatol; 2007 May; 156(5):1010-4. PubMed ID: 17408393
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis.
    Tyring S; Gordon KB; Poulin Y; Langley RG; Gottlieb AB; Dunn M; Jahreis A
    Arch Dermatol; 2007 Jun; 143(6):719-26. PubMed ID: 17576937
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Recovery of the response to biological treatments using narrow band ultraviolet-B in patients with moderate to severe psoriasis: a retrospective study of 17 patients.
    Belinchón I; Arribas MP; Soro P; Betlloch I
    Photodermatol Photoimmunol Photomed; 2014 Dec; 30(6):316-22. PubMed ID: 25132192
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effective treatment of etanercept and phototherapy-resistant psoriasis using the excimer laser.
    Park KK; Swan J; Koo J
    Dermatol Online J; 2012 Mar; 18(3):2. PubMed ID: 22483513
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis.
    Strober B; Teller C; Yamauchi P; Miller JL; Hooper M; Yang YC; Dann F
    Br J Dermatol; 2008 Aug; 159(2):322-30. PubMed ID: 18503600
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Etanercept plus narrowband ultraviolet B phototherapy of psoriasis is more effective than etanercept monotherapy at 6 weeks.
    Gambichler T; Tigges C; Scola N; Weber J; Skrygan M; Bechara FG; Altmeyer P; Kreuter A
    Br J Dermatol; 2011 Jun; 164(6):1383-6. PubMed ID: 21466532
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Changes in C-reactive protein in patients with moderate-to-severe psoriasis switched to adalimumab therapy after suboptimal response to etanercept, methotrexate or phototherapy.
    Strober BE; Poulin Y; Teller C; Wang Y; Williams DA; Goldblum OM
    J Eur Acad Dermatol Venereol; 2014 Dec; 28(12):1701-6. PubMed ID: 24422992
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Economic evaluation of etanercept in the management of chronic plaque psoriasis.
    Lloyd A; Reeves P; Conway P; Reynolds A; Baxter G
    Br J Dermatol; 2009 Feb; 160(2):380-6. PubMed ID: 18808413
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Relevance of compartmentalization of T-cell subsets for clinical improvement in psoriasis: effect of immune-targeted antipsoriatic therapies.
    van Lingen RG; Körver JE; van de Kerkhof PC; Berends MA; van Rens DW; Langewouters AM; Boezeman JB; Seyger MM; de Jong EM
    Br J Dermatol; 2008 Jul; 159(1):91-6. PubMed ID: 18476954
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Etanercept and efalizumab treatment for high-need psoriasis. Effects and side effects in a prospective cohort study in outpatient clinical practice.
    Berends MA; Driessen RJ; Langewouters AM; Boezeman JB; Van De Kerkhof PC; De Jong EM
    J Dermatolog Treat; 2007; 18(2):76-83. PubMed ID: 17520463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.